AlphAIAlphAI — Financial news for AI agents
investing.comOCT 262 min read$AARD

Aardvark Therapeutics stock rating cut to Perform by Oppenheimer

Oppenheimer downgraded Aardvark Therapeutics (NASDAQ:AARD) to Perform, withdrawing its $21 price target. The stock fell 63% to $0.98, near its 52-week low, after mixed Phase 3 study results. The company plans to seek FDA feedback on a revised study design and resume clinical activities in 2027. H.C. Wainwright also lowered its price target to $2, citing ongoing challenges.

Original reporting
investing.com
Published Oct 26, 2026, 6:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 6:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AARD
Bearish
high confidence
Mentioned
$AARD
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AARDBearishHigh
01

Why it matters

The downgrade reflects analyst concerns over trial uncertainties, likely prompting short‑term sell pressure.

02

Market read

Analyst downgrade on a micro‑cap biotech with fresh FDA hold‑lift news creates immediate trading relevance.

03

What to watch

Potential for lower‑dose Phase 3 design could reduce safety concerns and improve future valuation.

Relevance 8/10Novelty 8/10Timing: today

Background

Aardvark Therapeutics (NASDAQ:AARD) is a micro‑cap biotech developing ARD‑101 for hyperphagia in Prader‑Willi Syndrome. The FDA recently lifted a clinical hold, and the company released early Phase 3 data.

Company-level read

Ticker impact

$AARDBearishHigh confidence
Context

Oppenheimer cut Aardvark Therapeutics rating to Perform and withdrew its $21 price target after FDA lifted a clinical hold and released exploratory Phase 3 data.

Expected impact

likely pressure as investors price in the downgrade and lingering clinical uncertainties

Evidence & confidence

The downgrade is a fresh, material analyst action on a micro‑cap biotech, prompting immediate sell pressure.

Market effects

Sector

May dampen sentiment in the rare‑disease biotech sector as analysts scrutinize trial data.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Some investors may view the FDA hold lift as a positive catalyst despite the downgrade.

Key entities

  • company
    Aardvark Therapeutics

    Biotech developing ARD‑101 for Prader‑Willi Syndrome.

  • analyst_firm
    Oppenheimer

    Downgraded AARD to Perform and withdrew its $21 price target.

Read at source← All news

Related articles

OCT 23
$AARDMedAI 8/10

FDA Lifts Clinical Hold On Aardvark's ARD-101; PWS Program Targets 2027

Aardvark Therapeutics (AARD) reported exploratory data from its terminated Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome (PWS). The FDA lifted the clinical hold, and the company plans to seek guidance for a new Phase 3 trial, targeting 2027. ARD-101 showed modest efficacy in reducing hyperphagia but requires further study. AARD stock is down 48.67% year-to-date.

rttnews.com2 min
OCT 23
$AARDMedAI 8/10

Aardvark Reports Exploratory ARD-101 Data; FDA Lifts Clinical Hold

Aardvark reported exploratory data from the ARD-101 trial, showing reductions in hyperphagia scores. The FDA lifted the clinical hold on ARD-101, and the company plans to seek FDA input on a new Phase 3 trial, expecting to resume clinical activities in 2027. The trial showed modest efficacy and was generally well tolerated.

tradingview.com1 min
OCT 23
$AARDMedAI 9/10

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials • HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory • HQ-CT scores fell by Week 2 of dose escala

SEC EDGAR 8-K2 min
OCT 23
$AARDMedAI 8/10

Aardvark reports exploratory data from terminated PWS trial

Aardvark Therapeutics (NASDAQ:AARD) reported exploratory data from its terminated Phase 3 HERO trial for ARD-101, a treatment for Prader-Willi syndrome. The trial was stopped early with 67 participants. HQ-CT scores improved during treatment but rebounded after stopping. ARD-101 was generally well-tolerated, with one serious adverse event linked to a drug interaction.

investing.com2 min
OCT 23
$AARDMedAI 8/10

A hunger-drug trial stopped early; exploratory scores fell modestly, then neared baseline after treatment ended.

Aardvark Therapeutics (AARD) halted its Phase 3 HERO trial early, reporting exploratory data showing modest reductions in HQ-CT scores for ARD-101, a hunger-suppressing drug for Prader-Willi syndrome (PWS). Scores rebounded near baseline post-treatment. The FDA lifted its clinical hold, and Aardvark plans to meet with the FDA to design a new Phase 3 trial, aiming to resume PWS clinical activities in 2027. ARD-101 was generally well-tolerated, with mild to moderate adverse events.

stocktitan.net2 min
OCT 22
$AARDHighAI 8/10

Aardvark Therapeutics stock surges as FDA lifts clinical hold

Aardvark Therapeutics (NASDAQ:AARD) shares rose 21% after the FDA lifted its clinical hold on ARD-101, a drug for Prader-Willi Syndrome. The hold was placed in May 2026 after ECG changes were observed. Aardvark conducted additional studies and plans to resume trials. The company will review trial data in a webcast on October 23, 2026.

investing.com2 min